Studies with pairwise comparisons have suggested that CGRP monoclonal antibodies reduce monthly migraine days without increasing adverse events compared with placebo (Alasad and Asha, 2020; Deng et al., 2020). The gene discussed is CALCA; the disease is migraine disorder.